10例髓细胞肉瘤的临床分析  

Clinical Analysis of 10 Cases with Myeloid Sarcoma

作　　者：包芳[1] 王晶[1] 景红梅[1] 陈渝萍[1] 董菲[1] 胡凯[1] 刘彦[1] 王继军[1] 克晓燕[1] 

机构地区：[1]北京大学第三医院血液科,北京100191

出　　处：《肿瘤防治研究》2017年第6期409-412,共4页Cancer Research on Prevention and Treatment

基　　金：北京市自然科学基金(7132183)

摘　　要：目的探讨髓细胞肉瘤的临床特点及其预后。方法回顾性分析2001年至2014年北京大学第三医院血液科收治10例髓细胞肉瘤患者的资料,对其临床特点及预后进行总结。结果 10例患者中女性6例,男性4例,中位发病年龄为40.5岁,受累部位包括皮肤、乳腺、淋巴结、胸骨周围、宫颈、支气管,均接受化疗为主的治疗,5例死亡。中位生存期为12月,自诊断髓细胞肉瘤之日算起,最长存活240月。结论髓细胞肉瘤是一种罕见的局限性肿瘤,系统性化疗应在疾病确诊后尽快使用,造血干细胞移植可改善不良预后。Objective To analyze the clinical features, prognostic factors and treatment outcomes of myeloid sarcoma （MS）. Methods We analyzed retrospectively the clinical data and prognosis of 10 patients diagnosed as MS in the Department of Hematology in Peking University Third Hospital from 2001 to 2014. Results The median age of onset was 40.5 years, 6 female and 4 male patients. Affected areas included skin, breast, lymph nodes, parasternal area, cervix uteri, bronchus. All patients received chemotherapy and five patients were dead. Median survival was 12 months. The longest survival from diagnosis was 240 months. Conclusion Myeloid sarcoma （MS） is a rarely local tumor. Systemic chemotherapy should be used as soon as the diagnosis is confirmed. Hematopoietic stem cell transplantation can improve the poor prognosis.

关 键 词：髓细胞肉瘤 临床特点 预后 

分 类 号：R733[医药卫生—肿瘤]